Marker Therapeutics, Inc.

As of September 11, 2025, Marker Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish MACD and moving averages, and a year-to-date return of -69.13% compared to the S&P 500's 12.22%.

Marker Therapeutics, Inc. is considered risky and overvalued due to significant losses, a negative ROE of -85.09%, and a year-to-date return of -69.13%, which underperforms the S&P 500's 12.22%.

As of March 17, 2022, Marker Therapeutics, Inc. is classified as risky and overvalued, with a Price to Book Value of 1.38, an EV to Sales ratio of 1.11, a ROCE of -1272.49%, a P/E ratio of -1.3763, and a year-to-date return of -54.34%, significantly underperforming the S&P 500's 2.44%.

As of May 27, 2025, the trend is mildly bearish due to daily moving averages indicating a bearish trend, while weekly indicators show mixed signals, suggesting a lack of strong momentum.

As of March 2022, the management team of Marker Therapeutics, Inc. includes Mr. Frederick Wasserman (Independent Chairman), Mr. Peter Hoang (President and CEO), and Dr. Juan Vera (Chief Development Officer). The Board of Directors also features independent directors such as Mr. David Eansor and Mr. Steven Elms.

Marker Therapeutics, Inc. is an immuno-oncology company focused on developing peptide and gene-based immunotherapeutics and vaccines for cancer treatment. As of March 2025, it has a market cap of $16.97 million, with net sales of $0 million and a net loss of $4 million.

As of Jun 18, Marker Therapeutics, Inc. has a market capitalization of 16.97 million, classifying it as a Micro Cap company, with net sales of 5.70 million and a net profit of -12.79 million over the latest four quarters.